Skip to main content
OpenTrials

Clinical trial condition

Endometrial Endometrioid Adenocarcinoma

Explore clinical trials studying Endometrial Endometrioid Adenocarcinoma. Study availability and eligibility vary by location and protocol.

12 public trials 5 recruiting studies
Refine in advanced search Browse all conditions

Endometrial Endometrioid Adenocarcinoma trial results

Recruiting

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

NCT05256225

Conditions
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, +17 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
View all 414 locations
View Trial Details
Recruiting

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

NCT05112601

Conditions
Adenocarcinoma, Adnexal Diseases, Carcinoma, +28 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University Cancer and Blood Center LLC Athens, Georgia, United States
  • Augusta University Medical Center Augusta, Georgia, United States
  • Saint Alphonsus Cancer Care Center-Boise Boise, Idaho, United States
View all 138 locations
View Trial Details
Recruiting

Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial

NCT07436793

Conditions
Endometrial Endometrioid Adenocarcinoma, Endometrial Hyperplasia, Female Urogenital Diseases, +5 more
Locations
  • University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa, United States
  • University of New Mexico Cancer Center Albuquerque, New Mexico, United States
  • University of Utah Sugarhouse Health Center Salt Lake City, Utah, United States
  • University of Virginia Cancer Center Charlottesville, Virginia, United States
View Trial Details
Recruiting

Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer

NCT03422198

Conditions
Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Serous Adenocarcinoma, +6 more
Locations
  • Stanford Cancer Center Palo Alto, California, United States
  • Loyola University Medical Center Maywood, Illinois, United States
  • MD Anderson Houston, Texas, United States
  • Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States
View Trial Details
Active, not recruiting

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

NCT03914612

Conditions
Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, +30 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro Jonesboro, Arkansas, United States
View all 397 locations
View Trial Details
Active, not recruiting

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

NCT04214067

Conditions
Carcinosarcoma, Endometrial Endometrioid Adenocarcinoma, Neoplasms, +6 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Community Cancer Institute Clovis, California, United States
  • University Oncology Associates Clovis, California, United States
  • John Muir Medical Center-Concord Concord, California, United States
View all 280 locations
View Trial Details
Completed

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

NCT02020707

Conditions
Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma, +45 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Mayo Clinic in Rochester Rochester, Minnesota, United States
View Trial Details

Related conditions